TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $66,306.24 in Stock

TransMedics Group, Inc. (NASDAQ:TMDXGet Free Report) insider Tamer I. Khayal sold 736 shares of TransMedics Group stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $90.09, for a total transaction of $66,306.24. Following the completion of the sale, the insider now owns 14,375 shares of the company’s stock, valued at approximately $1,295,043.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

TransMedics Group Stock Performance

TransMedics Group stock opened at $88.66 on Friday. The company has a fifty day moving average price of $80.76 and a two-hundred day moving average price of $67.38. The company has a quick ratio of 10.13, a current ratio of 10.93 and a debt-to-equity ratio of 4.00. TransMedics Group, Inc. has a 12 month low of $36.42 and a 12 month high of $99.63.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently added to or reduced their stakes in the business. US Bancorp DE boosted its holdings in TransMedics Group by 70.4% in the fourth quarter. US Bancorp DE now owns 5,608 shares of the company’s stock worth $443,000 after purchasing an additional 2,317 shares during the period. D.A. Davidson & CO. boosted its holdings in TransMedics Group by 7.1% in the fourth quarter. D.A. Davidson & CO. now owns 9,220 shares of the company’s stock worth $728,000 after purchasing an additional 608 shares during the period. UBS Group AG boosted its holdings in TransMedics Group by 68.1% in the fourth quarter. UBS Group AG now owns 40,263 shares of the company’s stock worth $3,178,000 after purchasing an additional 16,309 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of TransMedics Group during the fourth quarter valued at $889,000. Finally, Level Four Advisory Services LLC acquired a new position in shares of TransMedics Group during the fourth quarter valued at $471,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

TMDX has been the subject of a number of research analyst reports. Morgan Stanley lifted their price target on shares of TransMedics Group from $54.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Monday, December 4th. JPMorgan Chase & Co. lifted their price target on shares of TransMedics Group from $67.00 to $70.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 7th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, TransMedics Group presently has a consensus rating of “Moderate Buy” and a consensus target price of $83.33.

Check Out Our Latest Stock Analysis on TransMedics Group

TransMedics Group Company Profile

(Get Free Report)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Featured Stories

Insider Buying and Selling by Quarter for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.